AI-powered wound care monitoring and assessment

AI-powered mobile application for assisted wound care monitoring and assessment, and the training of healthcare professionals and carers

In this project, we propose AI-based and serious-game based solutions to provide guidance and training to HCPs to document precisely the characteristics, treatment and evolution of wounds. The proposed AI-based innovation will also provide a clinical decision support system offering guidance on which treatment and dressings to use. To achieve this goal, imito AG is joining forces with the leading research partners in the domain of wound expertise (HEdS), AI (UNIGE) and healthcare-training (HEdS).

Imito, founded in 2016, is the leading provider of mobile wound care apps for hospitals, homecare and private practices in Germany and Switzerland with strong commercial partners such as Essity (BSN Medical) and Siemens Healthineers. We are now expanding into other countries in Europe.

In 2019, we created the imitoWound app for healthcare professionals to answer a recurrent demand from nurses and wound experts to radically simplify wound documentation. imitoWound is a CE marked, GDPR compliant medical device.

After the launch of imitoWound, we realized that many HCPs needed assistance for characterizing and documenting wounds correctly and for choosing the adapted treatment plan. There is a lack of expertise and teaching in the science of wound care assessment at the European and Swiss levels for both students and professionals. Indeed, HEdS, the partner of this project, is the only institution in Switzerland and mainland Europe to provide a specific curriculum in wound care to nurses and medical students.

The proposed innovation will strengthen our place on the EU market by increasing the revenue stream with a richer and smarter offering targeting a larger customer base. For the German market, Innosuisse will help us to comply with the KHZG (Hospital Future Act), and will facilitate the first step towards a DiGA (Digitale Gesundheitsanwendungen) application. Lastly, this innovation will help attract further investors for a series A (3M CHF) in 2022.

Dr. Guillaume Chanel
Dr. Guillaume Chanel
Head of the SIMS group

Developping user sensing